![Evolution Infographic: The Rise & Diversification of Biologics](https://evolution-bio.com/wp-content/uploads/2016/02/160223-biologics-featured.jpg)
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
![Evolution Analysis – Google, Sanofi, Novartis and the Race to Improve Diabetes Health Outcomes](https://evolution-bio.com/wp-content/uploads/2016/04/150910-news-google-sanofi-diabetes.jpg)
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
![Evolution Biopharma IPO Analysis featured on Forbes](https://evolution-bio.com/wp-content/uploads/2016/04/150826-evoforbes.jpg)
Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO
![Evolution Infographic – An Analysis of 2015 Therapeutic IPOs](https://evolution-bio.com/wp-content/uploads/2016/04/150803-infographic-ipo.jpg)
In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO